Amgen launches late-stage obesity trial in patients who switch from rival drugs

May 1, 2026 01:23 PM EDT R&D Am­gen launch­es late-stage obe­si­ty tri­al in pa­tients who switch from ri­val drugs Nicole DeFeudis Senior Reporter Am­gen is launch­ing three new late-stage tri­als for its long-act­ing obe­si­ty shot Mar­i­Tide, in­clud­ing one de­signed to test the drug in pa­tients switch­ing away from … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER